Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anemia; Kidney Diseases
Intervention: epoetin alfa (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The purpose of this study is to evaluate the hemoglobin response rate in subjects with
anemia, associated with chronic kidney failure, after receiving epoetin alfa (PROCRIT®)
every 2 weeks
Clinical Details
Official title: An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week Epoetin Alfa (PROCRIT)in the Treatment of Subjects With the Anemia of Chronic Kidney Disease (CKD)
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary endpoint is the number of subjects who achieve a hemoglobin response after receiving PROCRIT every 2 weeks. Hemoglobin response is defined as achieving a target hemoglobin range of 11-12 g/dL for at least 2 consecutive weeks by Week 28.
Secondary outcome: The secondary endpoints include: the time to a hemoglobin response, the number of subjects achieving a 1 g/dL rise in hemoglobin, change in quality of life measurements, and the total study drug dose up to the time of response.
Detailed description:
This is a prospective study in non-dialysis subjects with anemia associated with chronic
kidney disease. Subjects will be enrolled from multiple centers in the United States. The
primary objective of the study is to evaluate hemoglobin response rate. The secondary
objectives include evaluating the time to when hemoglobin responds, indicated by the results
of the hemoglobin blood levels, the change in hemoglobin over time, the transfusion
requirements and change in quality of life measurements. These measurements asks for the
subjects views about how one feels, activity and energy level, etc. The subjects are
administered study drug every 2 weeks through Study Week 27 unless dosing is held or the
subject withdraws from the study. Each injection of study drug should not exceed 1 ml in
volume.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects with chronic kidney disease and a glomerular filtration rate within 10-60
ml/min/1. 73m2 with no expected need for dialysis during the study
- subjects with a hemoglobin less than 11 g/dL
- subjects who have not received erythropoietic agents within 6 weeks before study
entry
- female subjects, with a reproductive potential, must have a negative urine pregnancy
test within 7 days of the first dose of study drug.
Exclusion Criteria:
- Subjects with poorly controlled high blood pressure (hypertension) - systolic > 150
mm Hg or diastolic > 100 mm Hg
- known hypersensitivity to human albumin and/or mammalian cell-derived products
- subjects receiving dialysis
- subjects with a ferritin level < 50 ng/mL, Transferrin Saturation < 20%
- subjects receiving chemotherapy for cancer within 1 month prior to study start or
expected during study participation
- Pregnancy or lactation.
Locations and Contacts
Additional Information
An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week PROCRIT (epoetin alfa) in the Treatment of Subjects with the Anemia of Chronic Kidney Disease
Starting date: May 2004
Last updated: May 19, 2011
|